cancer
AZ’s Tagrisso approved for untreated lung cancer in US
Tagrisso outperformed first-generation TKI drugs in FLAURA trial
‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade
Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.
AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC
Drug could become standard of care, says AZ
Clovis’ PARP drug gets new US ovarian cancer use
Rucaparib gets FDA OK in maintenance use
Incyte shares down sharply after phase 3 skin cancer trial failure
Trial tested epacadostat pill in combination with Merck & Co’s Keytruda
